Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
12
users have liked this narrative
8
users have commented on this narrative
49
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Immunocore Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Aging Demographics And Late-Stage Trials Will Expand Global Markets
Key Takeaways Expanding therapeutic portfolio and successful market entry reduce reliance on a single product and support a foundation for future revenue growth. Strong pricing power, effective cost management, and increased payer reimbursement position the company for stable margins and operational flexibility.
View narrative
US$62.00
FV
47.0% undervalued
intrinsic discount
15.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
4 days ago
author updated this narrative
SHCO
Soho House & Co
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Global Expansion And Operational Improvements Will Drive Future Performance
Key Takeaways Consistent membership growth and new house openings are expected to drive future revenue increases for Soho House & Co. Operational and strategic enhancements, including ERP systems and premium memberships, aim to boost profitability and improve net margins. Financial misstatements and strategic uncertainty may undermine investor confidence, impact strategic decisions, and pose risks to stable future revenue growth.
View narrative
US$9.00
FV
15.1% undervalued
intrinsic discount
7.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
AMC Entertainment Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Premium Cinema Experiences And Urban Venues Will Redefine Entertainment
Key Takeaways Premium formats, diversified content, and loyalty programs attract new audiences, boost ticket and concession sales, and drive stable, incremental revenue. Portfolio optimization, debt reduction, and strong cash management strengthen profitability, operational efficiency, and capacity for reinvestment.
View narrative
US$3.32
FV
9.6% undervalued
intrinsic discount
5.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
4 days ago
author updated this narrative
Teladoc Health
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Digital Chronic Care And International Expansion Will Unlock Future Markets
Key Takeaways Expanding digital chronic care programs and international presence positions Teladoc for sustainable revenue and membership growth by reaching more patients and underserved markets. Shifting business models and operational efficiencies, including AI-driven automation and insurance-based care, aim to enhance profitability, scalability, and user engagement.
View narrative
US$9.13
FV
17.6% undervalued
intrinsic discount
1.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
39
users have followed this narrative
4 days ago
author updated this narrative
6855
Ascentage Pharma Group International
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Key Takeaways Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth. Successful NASDAQ IPO and promising registrational trials position the company to accelerate pipeline development, enhancing future earnings potential.
View narrative
HK$75.50
FV
14.0% overvalued
intrinsic discount
19.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Everest Medicines
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
Key Takeaways Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks. Heavy investments in sales and R&D could strain margins if they fail to generate proportional revenue growth, impacting near-term earnings.
View narrative
HK$55.53
FV
27.1% overvalued
intrinsic discount
69.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
NetScout Systems
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Overoptimistic Cybersecurity Trends Will Exacerbate Valuation Risks
Key Takeaways Investor optimism hinges on NetScout's AI-driven cybersecurity growth and momentum in enterprise and federal segments, fueling high expectations for sustained revenue and margin expansion. Risks from cloud migration and IT stack consolidation may be underestimated, potentially threatening long-term stability of legacy products and current margin expectations.
View narrative
US$22.23
FV
0.8% overvalued
intrinsic discount
1.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
Global Net Lease
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Industrial And Logistics Focus Will Secure Stability Amid Office Risks
Key Takeaways Ongoing shift towards essential, resilient real estate sectors and high-quality tenants is aimed at ensuring stable revenue and long-term growth. Asset sales, leverage reduction, and focus on rent-escalating leases support earnings improvements, lower risk, and enhanced shareholder returns.
View narrative
US$9.42
FV
20.6% undervalued
intrinsic discount
-13.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
4 days ago
author updated this narrative
Wave Life Sciences
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
RNA Readouts And Clinical Milestones Will Broaden Treatment Horizons
Key Takeaways Positive early clinical data, expanded RNA platform validation, and accelerated trial progress strengthen Wave's position in competitive, growing markets for precision and RNA-based therapies. Strategic partnerships and non-dilutive funds provide financial stability, while increasing market and regulatory acceptance support sustainable growth and profitability.
View narrative
US$20.19
FV
51.7% undervalued
intrinsic discount
23.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies